Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Cancer Immunol Res. 2019 May 31;7(7):1202–1213. doi: 10.1158/2326-6066.CIR-18-0498

Figure 1. N-terminal amino acid trimming specificity by OPSCC ERAP1 allotype combinations.

Figure 1

E1KO 293T cells were transfected with ERAP1 allotype combinations from OPSCC patients together with H2-Kb and X-SHL8 minigenes representing 20 amino acids and assessed for generation of SHL8 by B3Z activation. OPSCC ERAP1 allotype identity from patients with TIL status are shown in panels (A) CD8/TILhigh, (B) CD8/TILmoderate, (C) CD8/TILLow, (D) CD8/TILhigh and CD8/TILmoderate, (E) CD8/TILhigh and CD8/TILlow and (F) CD8/TILmoderate and CD8/TILlow. The relative presentation of trimmed X-SHL8 was compared to that of the maximal response using SHL8, which does not require ERAP1 activity. Data pooled from four independent experimental repeats ±SEM.